Literature DB >> 31573475

Clinical features and current treatments of adult-onset Still's disease: a multicentre survey of 517 patients in China.

Qiong-Yi Hu1, Ting Zeng2, Chuan-Yin Sun3, Cai-Nan Luo4, Shuang Liu5, Ting-Ting Ding6, Zong-Fei Ji7, Anxin Lu8, Kuerbanjiang Yimaiti4, Jia-Lin Teng1, Xiao-Bing Cheng1, Jun-Na Ye1, Yu-Tong Su1, Hui Shi1, Yue Sun1, Hui-Hui Chi1, Zhuo-Chao Zhou1, Lin-Jie Chen6, Jian Xu5, Lin-Di Jiang7, Li-Jun Wu4, Jin Lin3, Cheng-De Yang9, Hong-Lei Liu10.   

Abstract

OBJECTIVES: As a rare systemic autoinflammatory disease, adult-onset Still's disease (AOSD) has heterogeneous clinical manifestations, response to treatment and outcome. This study tried to assess the clinical characteristics, laboratory tests, and treatments of Chinese AOSD patients, and make a retrospective analysis.
METHODS: We collected from 7 hospitals in China a total of 517 Chinese patients with AOSD who satisfied the Yamaguchi criteria. We retrospectively evaluated their clinical features, laboratory tests, treatments and compared them with published data from different studies. All the data in this study were from medical records and further statistic analyses.
RESULTS: We evaluated a total of 517 AOSD patients, 72% female, average age of onset was 37.7; spiking fever, rash and arthralgia occurred in 472 (91.3%), 413 (79.9%), 378 (73.1%) cases, respectively. There were 439/513 (85.6%) cases with leukocytosis and 456/476 (95.8%) cases with raised serum ferritin. The highest frequently used medications and regimens for remission were glucocorticoids (498/517, 96.3%), methotrexate (273/517, 52.8%) and hydroxychloroquine (174/517, 33.7%). 84.4%. 357/423 of AOSD cases were able to achieve initial remission with different regimens, mostly including glucocorticoids, methotrexate or hydroxychloroquine. 47.2% of them (244/517) received 30<D≤60 mg/d of prednisone to reach final clinical remission. Further analysis indicated that risk factors, such as skin rash, pericarditis, splenomegaly and delayed diagnosis, are highly related to the dosage of prednisone for remission.
CONCLUSIONS: Glucocorticoids are mostly selected to induce remission in China and half of them required ~0.5-1mg/kgbw prednisone. In patients with skin rash, pericarditis, splenomegaly or delayed diagnosis, a higher dosage of prednisone was needed to obtain remission.

Entities:  

Year:  2019        PMID: 31573475

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  11 in total

Review 1.  [Still's syndrome-similarities and differences between the juvenile and adult forms].

Authors:  Andrea Regel; Dirk Föll; Martin A Kriegel
Journal:  Z Rheumatol       Date:  2021-11-04       Impact factor: 1.372

2.  Adult-onset Still's disease evolving with multiple organ failure and death: A case report and review of the literature.

Authors:  Zhong-Bin Han; Ju Wu; Jing Liu; He-Ming Li; Kai Guo; Tong Sun
Journal:  World J Clin Cases       Date:  2021-02-06       Impact factor: 1.337

3.  Atypical adult-onset Still's disease with an initial and sole manifestation of liver injury: A case report and review of literature.

Authors:  Fan Yu; Shao-You Qin; Chang-Yu Zhou; Lu Zhao; Yan Xu; Er-Na Jia; Jiang-Bin Wang
Journal:  World J Clin Cases       Date:  2021-01-06       Impact factor: 1.337

4.  Serum Heparin-Binding Protein as a Potential Biomarker to Distinguish Adult-Onset Still's Disease From Sepsis.

Authors:  Rui Tian; Xia Chen; Chengde Yang; Jialin Teng; Hongping Qu; Hong-Lei Liu
Journal:  Front Immunol       Date:  2021-03-31       Impact factor: 7.561

5.  Detection and Prediction of Macrophage Activation Syndrome in Still's Disease.

Authors:  Clément Javaux; Thomas El-Jammal; Pierre-Antoine Neau; Nicolas Fournier; Mathieu Gerfaud-Valentin; Laurent Perard; Marine Fouillet-Desjonqueres; Julie Le Scanff; Emmanuelle Vignot; Stéphane Durupt; Arnaud Hot; Alexandre Belot; Isabelle Durieu; Thomas Henry; Pascal Sève; Yvan Jamilloux
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

6.  Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still's disease.

Authors:  Fumiaki Kondo; Takahiko Sugihara; Natsuka Umezawa; Hisanori Hasegawa; Tadashi Hosoya; Naoki Kimura; Masaaki Mori; Shinsuke Yasuda
Journal:  Arthritis Res Ther       Date:  2022-04-29       Impact factor: 5.606

7.  Adult-Onset Still's Disease-like Syndrome following COVID-19 Vaccination: A Case Report and Review of the Literature.

Authors:  Poramed Winichakoon; Wanitcha Chanloung; Teerapat Nantsupawat; Worawit Louthrenoo
Journal:  Vaccines (Basel)       Date:  2022-06-26

Review 8.  An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors:  Po-Ku Chen; Der-Yuan Chen
Journal:  J Immunol Res       Date:  2021-06-20       Impact factor: 4.818

9.  Urinary Proteomics Identifying Novel Biomarkers for the Diagnosis of Adult-Onset Still's Disease.

Authors:  Yue Sun; Fan Wang; Zhuochao Zhou; Jialin Teng; Yutong Su; Huihui Chi; Zhihong Wang; Qiongyi Hu; Jinchao Jia; Tingting Liu; Honglei Liu; Xiaobing Cheng; Hui Shi; Yun Tan; Chengde Yang; Junna Ye
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561

10.  Clinical phenotypes and prognostic factors of adult-onset Still's disease: data from a large inpatient cohort.

Authors:  Rui Li; Xiaolei Liu; Guangliang Chen; Guo Tang; Xiaoxiang Chen; Xuesong Liu; Juan Wang; Liangjing Lu
Journal:  Arthritis Res Ther       Date:  2021-12-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.